Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates

By sjmartinez • March 5, 2025

Pala L, Merlo F, Sala I, Pagan E, Oriecuia C, Specchia C, Catania C, Cocorocchio E, Laszlo D, Ceresoli G, Locatelli M, De Pas T, Zambelli A, Cortes J, Giaccone G, Moore KN, Bardia A, Viale G, Gelber RD, Bagnardi V, Conforti F. Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates. J Natl Cancer Inst. 2025 Feb 25:djaf049. doi: 10.1093/jnci/djaf049. Epub ahead of print. PMID: 40036179.

Tags: Hematology/Oncology, Publications

The association between statin use, genetic variation, and prostate cancer risk

Amiri A, Xu W, Zhang Q, Jeong JH, Freedland SJ, Fleshner NE, Finelli A, Hamilton RJ. The association between statin use, genetic variation, and prostate[...]

Clinician and Patient Perspectives on a Patient-Facing Online Breast Cancer Symptom Visualization Tool

Gresham G, Luu M, Henry NL, Nguyen T, Barnhill K, Yothers G, Kim S, Rogatko A, Attai DJ, Tighiouart M, Hays RD, Ganz PA. Clinician[...]

Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Patel PA, Collins RH Jr, Baer MR, Duong VH, Blum WG,[...]